Targeting CD19-positive lymphomas with the antibodydrug conjugate loncastuximab tesirine: preclinical evidence of activity as a single agent and in combination therapy.
Tarantelli C, Wald D, Munz N, Spriano F, Bruscaggin A, Cannas E, Cascione L, Gaudio E, Arribas AJ, Manjappa S, Golino G, Scalise L, Cacciapuoti MT, Zucca E, Stathis A, Inghirami G, Van Berkel PH, Rossi D, Caimi PF, Zammarchi F, Bertoni F.
Tarantelli C, et al. Among authors: bertoni f.
Haematologica. 2024 Oct 1;109(10):3314-3326. doi: 10.3324/haematol.2023.284197.
Haematologica. 2024.
PMID: 38721745
Free PMC article.